Protocol-Specific Research Support (PSRS) Innovative clinical research that involves early phase, investigator-initiated therapeutic trials or clinical trials emanating from the research activities of members of the University of Maryland Marlene and Stewart Greenebaum Cancer Center (LJMGCC) frequently requires funding to support research coordination, data management, and regulatory functions. Even when research grants provide partial funding or when drug supplies are provided free from commercial parties, additional support is necessary to move such trials forward, especially because per-patient costs are not reimbursed. PSRS will support research coordinators and data managers at UMGCC to facilitate these innovative clinical investigation efforts. Trials supported by PSRS will be subject to additional criteria for consideration by the Clinical Research Committee. The trials will be assigned a priority scale for funding based on (a) what innovation within the proposed PSRS-directed protocol will contribute to achieving a novel cancer diagnosis, treatment, imaging, or prevention strategy; (b) how critical correlative science will be enabled as a result of PSRS funding;and (c) what independent funding applications will emerge from the PSRS-supported trial. Twenty-four therapeutic protocols in UMGCC's portfolio and at least four new trials under development potentially qualify for this type of support. Accordingly, we are requesting PSRS of 25 percent each for two research coordinators and two data managers. This support will give UMGCC the flexibility to advance the cause of high-priority, innovative, early phase clinical trials. These trials will flow from investigator-initiated clinical research or will be the logical consequence of an alliance between basic scientists at UMGCC and clinicians who are suitable for addressing a translational science goal that is not incorporated into cooperative-group trials of the National Cancer Institute or industry-sponsored trials.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Maryland Baltimore
United States
Zip Code
Wang, Junxiang; Zhao, Liang; Ye, Yanfang et al. (2018) Adverse event detection by integrating twitter data and VAERS. J Biomed Semantics 9:19
Furusawa, Aki; Reiser, John; Sadashivaiah, Kavitha et al. (2018) Eomesodermin Increases Survival and IL-2 Responsiveness of Tumor-specific CD8+ T Cells in an Adoptive Transfer Model of Cancer Immunotherapy. J Immunother 41:53-63
Nathenson, Michael J; Conley, Anthony P; Sausville, Edward (2018) Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas. Oncologist 23:71-83
Wang, Lei; Felts, Sara J; Van Keulen, Virginia P et al. (2018) Exploring the effect of library preparation on RNA sequencing experiments. Genomics :
Nathenson, Michael J; Barysauskas, Constance M; Nathenson, Robert A et al. (2018) Surgical resection for recurrent retroperitoneal leiomyosarcoma and liposarcoma. World J Surg Oncol 16:203
Sallmyr, Annahita; Tomkinson, Alan E (2018) Repair of DNA double-strand breaks by mammalian alternative end-joining pathways. J Biol Chem 293:10536-10546
Kerr, Candace; Adhikary, Gautam; Grun, Daniel et al. (2018) Combination cisplatin and sulforaphane treatment reduces proliferation, invasion, and tumor formation in epidermal squamous cell carcinoma. Mol Carcinog 57:3-11
Connolly, Sean; Quasi-Woode, Devona; Waldron, Laura et al. (2018) Calcineurin Regulatory Subunit Calcium-Binding Domains Differentially Contribute to Calcineurin Signaling in Saccharomyces cerevisiae. Genetics 209:801-813
Pauza, C David; Liou, Mei-Ling; Lahusen, Tyler et al. (2018) Gamma Delta T Cell Therapy for Cancer: It Is Good to be Local. Front Immunol 9:1305
Wang, Lei; Felts, Sara J; Van Keulen, Virginia P et al. (2018) Integrative Genome-Wide Analysis of Long Noncoding RNAs in Diverse Immune Cell Types of Melanoma Patients. Cancer Res 78:4411-4423

Showing the most recent 10 out of 257 publications